Cingulate (NASDAQ:CING) Given “Buy” Rating at HC Wainwright

Cingulate (NASDAQ:CING)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a report issued on Tuesday,Benzinga reports. They presently have a $20.00 target price on the stock. HC Wainwright’s target price indicates a potential upside of 347.43% from the company’s previous close.

Several other research analysts also recently commented on CING. Weiss Ratings raised Cingulate from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday. Wall Street Zen cut Cingulate from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 16th. Roth Mkm restated a “buy” rating and set a $10.00 price objective on shares of Cingulate in a research report on Tuesday, May 19th. Finally, Ascendiant Capital Markets lowered their price objective on Cingulate from $58.00 to $55.00 and set a “buy” rating on the stock in a research report on Wednesday, April 8th. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Cingulate has a consensus rating of “Moderate Buy” and a consensus target price of $28.33.

Cingulate Price Performance

Shares of NASDAQ CING opened at $4.47 on Tuesday. The business’s 50 day moving average is $5.87 and its two-hundred day moving average is $5.33. The company has a market cap of $60.21 million, a P/E ratio of -1.06 and a beta of -0.81. Cingulate has a 12 month low of $3.20 and a 12 month high of $11.89.

Cingulate (NASDAQ:CING) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.53) by ($0.42). Sell-side analysts expect that Cingulate will post -2.44 earnings per share for the current fiscal year.

Institutional Trading of Cingulate

Several institutional investors have recently bought and sold shares of the stock. Kestra Advisory Services LLC boosted its stake in Cingulate by 14.8% in the 1st quarter. Kestra Advisory Services LLC now owns 140,000 shares of the company’s stock valued at $869,000 after buying an additional 18,000 shares in the last quarter. Geode Capital Management LLC boosted its stake in Cingulate by 43.9% in the 4th quarter. Geode Capital Management LLC now owns 61,035 shares of the company’s stock valued at $265,000 after buying an additional 18,629 shares in the last quarter. DRW Securities LLC acquired a new stake in Cingulate in the 4th quarter valued at $255,000. Renaissance Technologies LLC acquired a new stake in Cingulate in the 1st quarter valued at $198,000. Finally, Quantum Private Wealth LLC boosted its stake in Cingulate by 140.0% in the 3rd quarter. Quantum Private Wealth LLC now owns 24,000 shares of the company’s stock valued at $94,000 after buying an additional 14,000 shares in the last quarter. Institutional investors and hedge funds own 41.31% of the company’s stock.

Cingulate Company Profile

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.